GlassScriptPhysician profile
Stephen J Batter
NPI 1619069754
$5,775.06
in general payments reported to CMS, 2019-2025
46 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $283 · 2021: $583 · 2022: $694 · 2023: $698 · 2024: $1,170 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,853 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,853.16 |
| Education | $292.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $758.25 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $747.83 | 2019-2025 | Xtandi |
| 180 Medical, INC. | $420.58 | 2019-2025 | |
| Janssen Biotech, INC. | $326.10 | 2019-2025 | Erleada |
| Coloplast Corp | $290.55 | 2019-2025 | |
| Pfizer INC. | $253.20 | 2019-2025 | |
| Tolmar, INC. | $212.70 | 2023-2025 | Jatenzo, Eligard |
| Urogen Pharma, INC. | $208.23 | 2021-2025 | Jelmyto |
| Myovant Sciences INC. | $200.72 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $184.54 | 2022-2024 | Prolaris |
| Procept Biorobotics Corporation | $171.66 | 2024 | Aquabeam System |
| Accord Healthcare, INC. | $158.09 | 2022-2023 | |
| Amgen INC. | $148.52 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $139.60 | 2019-2025 | Adstiladrin |
| Tolmar Pharmaceuticals, INC. | $139.41 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Batter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.